

Pembrolizumab**Section**

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection

Indications

Melanoma of skin

Other specified malignant neoplasms of large intestine

Malignant neoplasms of cervix uteri

Adenocarcinoma of stomach

Malignant neoplasms of oesophagogastric junction

Squamous cell carcinoma of hypopharynx and variants

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Squamous cell carcinoma of nasopharynx

Therapeutic equivalent to [nivolumab](#) pour

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Carcinoma of breast, specialised type

Squamous cell carcinoma of oesophagus

Other specified malignant neoplasms of bronchus or lung